From: Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11)
 | Subjects | Mean age (SD), years | Mean height (SD), cm | Mean weight (SD), kg | Mean BMI (SD), kg/m2 | Male/female, n | Dosing | Dose (mg) | Placebo, n | hLF1-11, n | All, n |
---|---|---|---|---|---|---|---|---|---|---|---|
Study 1 | Healthy volunteers | 24 (5) | 185 (6) | 79 (9) | 23 (3) | 32/0 | Single | 0.005 | 2 | 6 | 8 |
 |  |  |  |  |  |  |  | 0.05 | 2 | 6 | 8 |
 |  |  |  |  |  |  |  | 0.5 | 2 | 6 | 8 |
 |  |  |  |  |  |  |  | 5.0 | 2 | 6 | 8 |
Study 2 | Healthy volunteers | 32 (12) | 183 (7) | 78 (12) | 23 (3) | 16/0 | Multiple | 0.5 | 2 | 6 | 8 |
 |  |  |  |  |  |  |  | 5.0 | 2 | 6 | 8 |
Study 3 | HSCT patients | 53 (8) | 178 (7) | 78 (14) | 24 (3) | 7/1 | Single | 5.0 | - | 8 | 8 |
 |  |  |  |  |  |  |  |  | 12 | 44 | 56 |